iTRAQ Analysis of Complex Proteome Alterations in 3xTgAD Alzheimer's Mice: Understanding the Interface between Physiology and Disease

Alzheimer's disease (AD) is characterized by progressive cognitive impairment associated with accumulation of amyloid β-peptide, synaptic degeneration and the death of neurons in the hippocampus, and temporal, parietal and frontal lobes of the cerebral cortex. Analysis of postmortem brain tissue from AD patients can provide information on molecular alterations present at the end of the disease process, but cannot discriminate between changes that are specifically involved in AD versus those that are simply a consequence of neuronal degeneration. Animal models of AD provide the opportunity to elucidate the molecular changes that occur in brain cells as the disease process is initiated and progresses. To this end, we used the 3xTgAD mouse model of AD to gain insight into the complex alterations in proteins that occur in the hippocampus and cortex in AD. The 3xTgAD mice express mutant presenilin-1, amyloid precursor protein and tau, and exhibit AD-like amyloid and tau pathology in the hippocampus and cortex, and associated cognitive impairment. Using the iTRAQ stable-isotope-based quantitative proteomic technique, we performed an in-depth proteomic analysis of hippocampal and cortical tissue from 16 month old 3xTgAD and non-transgenic control mice. We found that the most important groups of significantly altered proteins included those involved in synaptic plasticity, neurite outgrowth and microtubule dynamics. Our findings have elucidated some of the complex proteome changes that occur in a mouse model of AD, which could potentially illuminate novel therapeutic avenues for the treatment of AD and other neurodegenerative disorders.

[1]  M. Celio,et al.  Parvalbumin in most gamma-aminobutyric acid-containing neurons of the rat cerebral cortex. , 1986, Science.

[2]  P. Fraser,et al.  Identification of syntaxin 1A as a novel binding protein for presenilin-1. , 2000, Brain research. Molecular brain research.

[3]  Jun Ren,et al.  The emerging role of coenzyme Q-10 in aging, neurodegeneration, cardiovascular disease, cancer and diabetes mellitus. , 2005, Current neurovascular research.

[4]  J. Wesson Ashford,et al.  APOE genotype effects on alzheimer’s disease onset and epidemiology , 2007, Journal of Molecular Neuroscience.

[5]  S. DeKosky,et al.  Structural correlates of cognition in dementia: quantification and assessment of synapse change. , 1996, Neurodegeneration : a journal for neurodegenerative disorders, neuroprotection, and neuroregeneration.

[6]  N. Barbaro,et al.  Calcium‐binding protein (calbindin‐D28K) and parvalbumin immunocytochemistry in the normal and epileptic human hippocampus , 1991, The Journal of comparative neurology.

[7]  Shu-Dong Zhang,et al.  A statistical framework for the design of microarray experiments and effective detection of differential gene expression , 2004, Bioinform..

[8]  J. Burthem,et al.  The use of isobaric tag peptide labeling (iTRAQ) and mass spectrometry to examine rare, primitive hematopoietic cells from patients with chronic myeloid leukemia , 2007, Molecular biotechnology.

[9]  N. Kowall,et al.  Immunohistochemical patterns of selective cellular vulnerability in human cerebral ischemia , 1993, Journal of the Neurological Sciences.

[10]  K. Jellinger,et al.  Tau and alpha-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs. , 2007, Acta neuropathologica.

[11]  E. Hertzberg,et al.  Elevated connexin43 immunoreactivity at sites of amyloid plaques in alzheimer's disease , 1996, Brain Research.

[12]  M. Beal Mitochondrial Dysfunction and Oxidative Damage in Alzheimer's and Parkinson's Diseases and Coenzyme Q10 as a Potential Treatment , 2004, Journal of bioenergetics and biomembranes.

[13]  J. D. McGaugh,et al.  Intraneuronal Aβ Causes the Onset of Early Alzheimer’s Disease-Related Cognitive Deficits in Transgenic Mice , 2005, Neuron.

[14]  E. Masliah Recent advances in the understanding of the role of synaptic proteins in Alzheimer's Disease and other neurodegenerative disorders. , 2001, Journal of Alzheimer's disease : JAD.

[15]  M. C. Alliegro A C-terminal carbohydrate-binding domain in the endothelial cell regulatory protein, pigpen: new function for an EWS family member. , 2000, Experimental cell research.

[16]  D. Butterfield,et al.  Redox proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: insights into the progression of this dementing disorder. , 2007 .

[17]  M. Mattson,et al.  Prophylactic treatment with paroxetine ameliorates behavioral deficits and retards the development of amyloid and tau pathologies in 3xTgAD mice , 2007, Experimental Neurology.

[18]  Satoshi Minoshima,et al.  Posterior cingulate cortex in Alzheimer's disease , 1994, The Lancet.

[19]  S. Paul,et al.  Diazepam-binding inhibitor. A brain neuropeptide present in human spinal fluid: studies in depression, schizophrenia, and Alzheimer's disease. , 1986, Archives of general psychiatry.

[20]  G. Churchill,et al.  Sex, flies and microarrays , 2001, Nature Genetics.

[21]  E. Masliah Natural evolution of the neurodegenerative alterations in Alzheimer's disease , 1995, Neurobiology of Aging.

[22]  R. Faull,et al.  A comparative proteome analysis of hippocampal tissue from schizophrenic and Alzheimer's disease individuals , 1999, Molecular Psychiatry.

[23]  M. Mattson,et al.  Triple-Transgenic Model of Alzheimer's Disease with Plaques and Tangles Intracellular Aβ and Synaptic Dysfunction , 2003, Neuron.

[24]  Sudarshan C Upadhya,et al.  Role of the ubiquitin proteasome system in Alzheimer's disease , 2007, BMC Biochemistry.

[25]  H. Braak,et al.  Occurrence of neuropil threads in the senile human brain and in Alzheimer's disease: A third location of paired helical filaments outside of neurofibrillary tangles and neuritic plaques , 1986, Neuroscience Letters.

[26]  B. Bergamasco,et al.  Diazepam binding inhibitor-like immunoreactivity (DBI-LI) in human CSF Correlations with neurological disorders , 1988, Journal of the Neurological Sciences.

[27]  S. Scheff,et al.  Synaptic pathology in Alzheimer’s disease: a review of ultrastructural studies , 2003, Neurobiology of Aging.

[28]  S. Snyder,et al.  S-nitrosylated GAPDH initiates apoptotic cell death by nuclear translocation following Siah1 binding , 2005, Nature Cell Biology.

[29]  H. Braak,et al.  Evolution of the neuropathology of Alzheimer's disease , 1996, Acta neurologica Scandinavica. Supplementum.

[30]  R. Faull,et al.  Differential sensitivity of calbindin and parvalbumin immunoreactive cells in the striatum to excitotoxins , 1991, Brain Research.

[31]  Taizen Nakase,et al.  Gap junctions and neurological disorders of the central nervous system. , 2004, Biochimica et biophysica acta.

[32]  K. Jellinger,et al.  Tau and α-synuclein brainstem pathology in Alzheimer disease: relation with extrapyramidal signs , 2006, Acta Neuropathologica.

[33]  L. Mucke,et al.  100 Years and Counting: Prospects for Defeating Alzheimer's Disease , 2006, Science.

[34]  B. Hyman,et al.  Alzheimer's disease is a laminar, regional, and neural system specific disease, not a global brain disease , 1994, Neurobiology of Aging.

[35]  C. Burdsal,et al.  Mouse pigpen encodes a nuclear protein whose expression is developmentally regulated during craniofacial morphogenesis , 2003, Developmental dynamics : an official publication of the American Association of Anatomists.

[36]  L R Squire,et al.  Lesions of the hippocampal formation but not lesions of the fornix or the mammillary nuclei produce long-lasting memory impairment in monkeys , 1989, The Journal of neuroscience : the official journal of the Society for Neuroscience.

[37]  R. Lefkowitz,et al.  The β2-Adrenergic Receptor Mediates Extracellular Signal-regulated Kinase Activation via Assembly of a Multi-receptor Complex with the Epidermal Growth Factor Receptor* , 2000, The Journal of Biological Chemistry.

[38]  E. Masliah,et al.  Cycles of Aberrant Synaptic Sprouting and Neurodegeneration in Alzheimer's and Dementia with Lewy Bodies , 2003, Neurochemical Research.

[39]  Bing Zhang,et al.  WebGestalt: an integrated system for exploring gene sets in various biological contexts , 2005, Nucleic Acids Res..

[40]  Virginia M. Y. Lee,et al.  Increased Lipid Peroxidation Precedes Amyloid Plaque Formation in an Animal Model of Alzheimer Amyloidosis , 2001, The Journal of Neuroscience.

[41]  W. Honer,et al.  Synaptic Pathology in Prefrontal Cortex is Present Only with Severe Dementia in Alzheimer Disease , 2001, Journal of neuropathology and experimental neurology.

[42]  R. Lefkowitz,et al.  The beta(2)-adrenergic receptor mediates extracellular signal-regulated kinase activation via assembly of a multi-receptor complex with the epidermal growth factor receptor. , 2000, The Journal of biological chemistry.

[43]  R A Irizarry,et al.  On the utility of pooling biological samples in microarray experiments. , 2005, Proceedings of the National Academy of Sciences of the United States of America.

[44]  S. Hecht,et al.  Chemopreventive agents modulate the protein expression profile of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone plus benzo[a]pyrene-induced lung tumors in A/J mice. , 2007, Carcinogenesis.

[45]  M. Mattson Pathways towards and away from Alzheimer's disease , 2004, Nature.

[46]  D. Lahiri,et al.  Neuronal Differentiation Is Accompanied by Increased Levels of SNAP‐25 Protein in Fetal Rat Primary Cortical Neurons , 2006, Annals of the New York Academy of Sciences.

[47]  A. Ferreira,et al.  Beta-amyloid disrupted synaptic vesicle endocytosis in cultured hippocampal neurons , 2007, Neuroscience.

[48]  D. Butterfield,et al.  P4-162: Proteomics identification of oxidatively modified brain proteins in Alzheimer's disease and mild cognitive impairment: Insights into the progression of this dementing disorder , 2008, Alzheimer's & Dementia.

[49]  J. Trojanowski,et al.  Relationship between plaques, tangles, and dystrophic processes in Alzheimer's disease , 1995, Neurobiology of Aging.

[50]  Y. Koshino,et al.  14‐3‐3 protein beta isoform is associated with 3‐repeat tau neurofibrillary tangles in Alzheimer's disease , 2007, Psychiatry and clinical neurosciences.

[51]  R. Cole,et al.  Quantitative Proteomics Analysis of Human Endothelial Cell Membrane Rafts , 2007, Molecular & Cellular Proteomics.

[52]  G. McMullan,et al.  A semi-quantitative GeLC-MS analysis of temporal proteome expression in the emerging nosocomial pathogen Ochrobactrum anthropi , 2007, Genome Biology.

[53]  J Carter,et al.  Molecular Pathology of Alzheimer's Disease , 2013 .

[54]  H. Budka,et al.  Natively unfolded tubulin polymerization promoting protein TPPP/p25 is a common marker of alpha-synucleinopathies , 2004, Neurobiology of Disease.

[55]  D. Purich,et al.  Self-assembly of the brain MAP-2 microtubule-binding region into polymeric structures resembling Alzheimer filaments. , 1996, Biochemical and biophysical research communications.

[56]  R. Cole,et al.  Proteome of murine jejunal brush border membrane vesicles. , 2007, Journal of proteome research.

[57]  K. Akagawa,et al.  Syntaxin 5 interacts with presenilin holoproteins, but not with their N- or C-terminal fragments, and affects beta-amyloid peptide production. , 2004, The Biochemical journal.

[58]  Xin-peng Dun,et al.  [Diazepam-binding inhibitor]. , 2005, Sheng li ke xue jin zhan [Progress in physiology].